Mount Sinai, Theragene Form Partnership to Move Potential PH Gene Therapy to Clinical Development – Pulmonary Hypertension News
Pulmonary Hypertension News |
Mount Sinai, Theragene Form Partnership to Move Potential PH Gene Therapy to Clinical Development
Pulmonary Hypertension News New York's Mount Sinai and Theragene Pharmaceuticals have joined efforts to move a novel investigational aerosol-delivered gene therapy to treat pulmonary hypertension (PH) into a clinical development program. The new therapy, if approved, will be the … |
